What did ReNerve Limited (ASX:RNV) announce regarding its Asian market expansion?

ReNerve has secured a three-year exclusive distribution agreement with Swedish Trading Company Limited (STC) to commercialise its NervAlign peripheral nerve injury repair products. The partnership covers Hong Kong, Macau, and the Greater Bay Area,

Who is ReNerve’s (ASX:RNV) new partner and what are their specific responsibilities?

ReNerve has partnered with the Swedish Trading Company Limited (STC), a premier medical device distributor headquartered in Hong Kong. Under the binding terms, STC will handle all operational responsibilities, including the importation, warehousing, strategic marketing, and regional sales of NervAlign products.

What role will ReNerve Limited (ASX:RNV) maintain under the new distribution agreement?

While STC manages the regional supply chain and sales, ReNerve is responsible for delivering continuous clinical and technical support. The company will also provide specialised training and handle regulatory liaison services to support the commercial rollout.

How large is the target market for ReNerve’s (ASX:RNV) NervAlign products in this territory?

The distribution agreement unlocks access to a massive combined addressable population of approximately 88 million people across Hong Kong, Macau, and the Greater Bay Area. Management views this region as one of Asia's most dynamic and well-resourced healthcare markets for advanced nerve repair.

What is the current operational status of the ReNerve (ASX:RNV) commercial rollout?

The commercial rollout is already underway, and the partnership has transitioned from planning to execution. ReNerve and STC are currently shipping the initial stocking orders directly to the Hong Kong market to meet immediate clinical demand.

Image for illustrative purposes only. Not a real photo.

ReNerve wins exclusive three-year Asian distribution deal

Written by Jon CuthbertPublished Jun. 1 2026Last Updated Jun. 1 2026

ReNerve (ASX:RNV) secured a three-year exclusive distribution agreement with the Swedish Trading to commercialise its innovative NervAlign peripheral nerve injury repair products across Hong Kong, Macau, and the Greater Bay Area.

The partnership follows closely on the heels of ReNerve's expanded regulatory approvals within the highly dynamic jurisdictions, unlocking access to a combined addressable population of approximately 88 million people.

Under the binding terms, STC—a premier medical device distributor headquartered in Hong Kong—will assume full operational responsibility for the importation, warehousing, strategic marketing, and regional sales operations.

In return, ReNerve will deliver continuous clinical and technical support, specialised training, and regulatory liaison services.

The commercial rollout is already underway, with the initial stocking orders currently being shipped to the Hong Kong market to meet immediate clinical demand.

ReNerve CEO Dr Julian Chick emphasised that securing a partner of STC's calibre represents a profound milestone, capitalising directly on recent regulatory momentum.

By leveraging STC’s deeply entrenched relationships with elite clinical networks and hospital systems, ReNerve is positioned to address a critical, unmet medical need in advanced nerve repair.

At the time of reporting, ReNerve’s share price was $0.083.